During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …

Purpose The aim of this study was to evaluate the efficacy and safety of 177 Lu-PSMA-617
radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). Methods In …

Bone metastasis develops in multiple malignancies with a wide range of incidence. The
presence of multiple bone metastases, leading to a multitude of complications and poorer …

Many solid cancers metastasize to the bone and bone marrow (BM). This process may occur
even before the diagnosis of primary tumors, as evidenced by the discovery of disseminated …

Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy
(PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients …

Background: The potential benefit of administering external beam radiation therapy (EBRT)
to patients with asymptomatic bone metastases has rarely been addressed in clinical …

Radium-223 dichloride (223Ra) is the first, recently approved, α-particle-emitting
radiopharmaceutical for the treatment of patients with bone metastases in castration …

Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu] Lu-
PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer …

Simple Summary In this review, we summarize the risk factors of prostate cancer (PCa),
mechanism of PCa induced bone metastasis, current treatments for PCa induced bone …